Improved supportive care, more precise risk stratification, and personalized chemotherapy based on the characteristics of leukemic cells and hosts (e.g., pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood acute lymphoblastic leukemia to near 90%. Further increase in cure rate can be expected from the discovery of additional recurrent molecular lesions, coupled with the development of novel targeted treatment through high-throughput genomics and innovative drugscreening systems. We discuss specific areas of research that promise to further refine current treatment and to improve the cure rate and quality of life of the patients.
Introduction
Optimal use of existing antileukemic agents and improved supportive care in contemporary clinical trials have improved the 5-year survival rate of childhood acute lymphoblastic leukemia (ALL) above 85% in developed countries (Table 1) . [1] [2] [3] [4] [5] [6] [7] [8] Further advances in survival and quality of life will require a better understanding of ALL pathobiology, the mechanisms of drug resistance, and drug disposition in the host, together with the development of innovative therapeutics. To this end, the advent of highresolution genome-wide analyses of gene expression, DNA copy number alterations, and epigenetic changes, and more recently, next-generation whole-genome and transcriptome sequencing have provided new insights into leukemogenesis, drug resistance and host pharmacogenomics, identified novel subtypes of leukemia, and suggested potential targets for therapy. 9, 10 Paralleling these advances has been the development of novel monoclonal antibodies, small molecule inhibitors, chemotherapeutics and cell-based treatment strategies. 9 Here we discuss some of the current challenges and future directions in pediatric ALL research.
Emerging leukemia subtypes
Traditionally, ALL has been classified into precursor T (or T-cell), precursor B, and B-cell (Burkitt's) phenotypes which are then further subdivided according to recurrent karyotypic abnormalities including aneuploidy and translocations. 9, 11 Detailed profiling of submicroscopic alterations and mutational analyses have allowed refinement of these classification schema, identification of genetic alterations that coexist and cooperate with chromosomal alterations in leukemogenesis, and discovery of new ALL subtypes that lack alterations on cytogenetic analysis. Like acute myeloid leukemia, 12 many ALL subtypes are characterized by genetic alterations that perturb multiple key cellular
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Recent studies have identified a novel high-risk immature T-cell subtype, termed "early T-cell precursor" ALL, which is characterized by immunological markers and a gene expression profile reminiscent of double-negative 1 thymocytes that retain the ability to differentiate into both T-cell and myeloid, but not B-cell, lineages. 13 Whole genome sequencing showed that the mutational spectrum of this subtype shares characteristics of acute myeloid leukemia, and the transcriptional profile of the blasts is similar to that of normal hematopoietic stem cells and granulocyte-macrophage precursors,
suggesting that this subtype of leukemia is a stem-cell disease. 14 The mutations frequently involve genes regulating hematopoietic development (GATA3, ETV6, RUNX1, IKZF1 and EP300), cytokine receptor and RAS signaling (NRAS, KRAS, FLT3, IL7R, JAK3, JAK1, SH2B3, and BRAF), and histone modification (EZH2, EED, SUZ12, SETD2 and EP300). These findings suggests that patients with early T-cell precursor ALL may benefit from new therapies that exploit the myeloid or stem cell features of this leukemia such as high-dose cytarabine or epigenetic therapy, 14 a hypothesis that remains to be proven.
Although several specific genetic abnormalities have been recognized to have prognostic or therapeutic relevance, 9 there is no consensus on the specific genotypes used for treatment stratification. Thus, different favorable (hyperdiploidy>50; trisomies 4, 10 and 17; ETV6-RUNX1) and unfavorable
(hypodiploidy <44; intrachromosomal amplification of chromosome 21 [iAMP21]; BCR-ABL1)
genotypes have been used by various study groups to direct therapy. 9, [15] [16] [17] [18] Pre-B ALL with the t(1;19) (q23;p13) and expression of the TCF3-PBX1 fusion, once considered a high-risk entity, is not even prospectively identified by some study groups because of the improved outcome with contemporary treatment regimens. We assert that this genotype should still be identified for intensification of intrathecal therapy because of its associated risk of central-nervous-system (CNS) relapse in the to identify these subtypes and partly because of their recent discovery, they have yet to be incorporated into risk stratification systems in the contemporary clinical trials. However, we would test patients with refractory or relapsed leukemia for these subtypes, as they may benefit from targeted therapy (discussed below).
Potential therapeutic targets: the search for personalized medicine
The remarkable improvement of early treatment outcome in children with BCR-ABL1-positive ALL with the addition of an ABL1 tyrosine kinase inhibitor (imatinib) to an intensive treatment regimen of the COG, 18 including a high cumulative dose of alkylating agent and cranial irradiation, has fueled enthusiasm for developing an even more effective targeted therapy for this ALL subtype. An international study has been initiated to test whether the intensity of chemotherapy can be reduced and cranial irradiation limited to only patients with overt CNS leukemia at diagnosis by substitution of imatinib with a more potent second-generation inhibitor (dasatinib) that penetrates readily to the CNS.
Recent insights gained from genome-wide analyses have identified novel genetic alterations, some of which have clinical relevance and others could also serve as therapeutic targets in childhood ALL ( 54, 55 There is substantial ancestral diversity among children with ALL ( Figure 2) . A recent study showed that Native American ancestry is significantly associated with a poor outcome among patients of Hispanic ethnicity, and even within patients self-reporting as white, and that its adverse prognosis could be abrogated by an additional course of delayed intensification therapy.
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Despite their loss of adverse prognostic impact in the context of contemporary effective treatment, many features still have therapeutic implications, with their presence indicating the need for modified therapy. Table 3 lists some characteristics of the leukemic cells and host that can be used for therapeutic intervention. To this end, even low-risk patients may require some degree of intensified therapy to achieve a high cure rate. This point is well illustrated by recent experience in our Total Therapy XV study, where treatment with intensive asparaginase and perhaps also high-dose methotrexate might have contributed to the outstanding outcome of patients with ETV6-RUNX1 fusion, especially those with poor early treatment response.
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It is well recognized that there is heterogeneity within each genetic subtype of ALL, partly because of differences in cooperating mutations or the target cell that undergoes malignant transformation, and partly because of variable host factors. 11 Not surprisingly, the response to remission induction therapy as determined by MRD level is the most important prognostic indicator in patients with ALL because it accounts for the entire constellation of leukemic-cell biologic features (intrinsic drug sensitivity), host pharmacodynamics and pharmacogenomics, treatment adherence, and efficacy of the treatment regimen. 11 If so, why did the level of MRD at the end of remission induction lack prognostic significance in a recent COG study for Philadelphia chromosome-positive ALL, 18 and remission induction failure did not predict a dire outcome of precursor B-cell ALL without other adverse features in an international cooperative group study? 58 A possible explanation is that the ABL1 tyrosine kinase
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From inhibitor was not used during remission induction in the COG study, and antimetabolites (including high-dose methotrexate) which are effective treatment components for precursor B-cell ALL (especially those with hyperdiploidy) tend to be used only after remission induction. These two scenarios should prompt reassessment of the current indications for hematopoietic stem cell transplantation in first complete remission, which should be reserved for patients with leukemia that is refractory to contemporary most effective combination chemotherapy, as documented by the MRD assay. In this regard, St. Jude Total XV study used MRD level at day 46 of remission induction (after treatment with prednisone, vincristine, daunorubicin, asparaginase, cyclophosphamide, cytarabine and mercaptopurine treatment ) for final risk assessment. 7 Likewise, in the AIEOP-BFM-ALL 2000 study, MRD at the second time point on day 78 (after treatment with the same 7 drugs) was found to be the most important predictor of treatment outcome, superseding the MRD result at the first time point on day 33 (after treatment with the first 4 drugs).
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Optimizing remission induction therapy
Although protocols for pediatric ALL rely on the same classes of drugs for remission induction, there is no consensus on what constitutes an optimal regimen. Virtually all study groups in developed countries can achieve an overall complete remission rate of 98% to 99%. Whether there are differences in the rate of "molecular" or "immunological" remission (i.e., <0.01% leukemic cells in bone marrow) among different clinical trials is unknown. However, it should be emphasized that neither molecular nor immunological remission after induction therapy is required for cure. Indeed, early studies showed that intensive induction therapy may not be necessary for standard-risk patients, provided that they receive adequate postremission intensification therapy. 60, 61 In our Total XV study, patients with an MRD level of 0.01% to 0.99% at the end of induction received intensified postremission therapy and achieved a 5-
year survival of 90.9% ± 5.4%, a rate similar to that (94.5% ± 1.9%) for patients who had negative MRD at the end of induction therapy. 7 In view of the many examples of increased early morbidity and mortality in protocols featuring intensive induction therapy, 60, 62 remission induction should be moderate in intensity for standard-risk patients, especially in low income countries where resources are less abundant and among patients with Down syndrome who are more susceptible to fatal infectious complications. 63 In fact, myelosuppressive therapy should be temporarily delayed in the presence of infection during induction, even in high-risk patients. To this end, we measure MRD level after 2 weeks of remission induction, and use the result to guide the intensity of the subsequent induction therapy. This approach is especially desirable in low income countries where identification of good early responders to avoid over-treatment can pay large dividends in terms of reduced morbidity and mortality. Based on the finding of exquisite sensitivity of normal bone marrow lymphoid progenitors (CD19 + , CD10 + , and/or CD34 + ) to corticosteroids and other antileukemic drugs, a simple and inexpensive assay for MRD detection has been developed to identify such patients during remission induction therapy. 64 Remission induction therapy invariably includes a glucocorticoid, vincristine and asparaginase, not only because they are non-myelosuppressive but also because they have distinct mechanisms for their antileukemic effects and may act synergistically. 57, 65 Prednisone has traditionally been the glucocorticoid most commonly used in remission induction, but dexamethasone has increasingly replaced prednisone in recent clinical trials. 66 Two recent studies showed that dexamethasone, given at 10 mg/m 2 per day during remission induction, improved outcome in patients with T-cell ALL and a good response to 7 days of upfront prednisone treatment, and in children under 10 years of age with precursor B-cell ALL, as compared to prednisone administered at 60 mg/m 2 per day. 67, 68 However, it should be noted that the efficacy of prednisone and dexamethasone is dose dependent and when the 1 1 dose ratio of prednisone to dexamethasone is greater than 7, event-free survival estimates are comparable with the two drugs, although dexamethasone still appears to yield improved CNS control. 66 These findings notwithstanding, an excellent outcome can also be achieved with a relatively low dose of prednisone (40 mg/m 2 per day) during remission induction, provided that postremission treatment is adequate and includes dexamethasone, as shown in our Total XV study. 7 Dexamethasone at a dose of 10 mg/m 2 is not recommended for remission induction in children ≥ 10 years of age with precursor Bcell ALL because of the high rates of toxicity and toxic death associated with the treatment, 67 a finding partly related to the slower clearance of dexamethasone in this age group. For patients who receive such high dose, we would also individualize the dosage to achieve the desired steady-state plasma concentration (65 µM) not only to optimize antileukemic effects but also to reduce toxicity ( Figure 3 ).
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Selecting effective consolidation/intensification/reinduction therapy
Delayed intensification with asparaginase, vincristine, and dexamethasone, with or without anthracycline, mercaptopurine and methotrexate, is the most widely used strategy in ALL protocols, and is beneficial to all patients. 7, [74] [75] [76] In COG studies, intensification treatment for 6 months is as effective as 10 months of such therapy for standard-risk patients and high-risk patients with a rapid early response. 75 Whether high-risk slow early responders would benefit from prolonged intensification therapy remains uncertain. Notably, altered dosing of dexamethasone during delayed intensification, by giving it on days 1 to 7 and days 15 to 21 for two courses rather than on days 1 to 21
for one course, significantly reduced the incidence of osteonecrosis in a COG study. 75 One of the key components of this phase of treatment is asparaginase, which is available in several formulations with different pharmacokinetic profiles. 77 In terms of leukemia control, the dose intensity and duration of asparaginase therapy are more important than the type of asparaginase used. Because of lower immunogenicity, less frequent administration, and the feasibility of intravenous administration, the pegylated form of Escherichia coli asparaginase (PEG-asparaginase) has replaced the native Escherichia coli product as the first-line treatment for children in the USA and is being used increasingly in other clinical trials around the world. In general, the preparation derived from Erwinia chrysanthemia, which lacks cross-reactivity with E. coli preparation, is used as second-or third-line therapy for patients with hypersensitivity reactions to native E. coli or PEG-asparaginase. 77 Depending on the preparation used, the treatment schedule and concomitant immunosuppressive therapy, 10% to 60% of the patients would develop hypersensitivity reactions due to the production of anti-asparaginase antibody. 77 A third of the patients without clinical hypersensitivity reactions may also develop IgG antibodies that can inactivate asparaginase, leading to suboptimal asparagine depletion, a
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From phenomenon commonly referred to as "silent inactivation." 78 The presence of IgG antibodies, with or without clinical hypersensitivity, can lead not only to decreased exposure to asparaginase but also to high clearance of dexamethasone when given concomitantly, presumably due to lower asparaginase effects on the production of hepatic enzymes involved in dexamethasone metabolism. 79 However, the presence of asparaginase antibody is an inconsistent prognostic indicator of leukemia-free survival, perhaps because its adverse effect can be mitigated by the use of an alternative asparaginase preparation or by the overall efficacy of the treatment regimen. 77 Routine antibody monitoring is not being implemented in current practice, partly because the prognostic impact of the presence of antibody is variable and partly because there are no commercially available kits to measure it. These issues, notwithstanding, antibody testing could be useful in some clinical conditions. First, measurement of antibodies is an excellent tool for diagnosing clinical hypersensitivity in patients with ambiguous symptoms or signs of allergy. 78, 80 Second, PEGasparaginase treatment can still yield a therapeutic level of asparaginase in patients with low-tointermediate antibody levels against E coli asparaginase. 80 Third, some patients may have antibodies to the nonprotein PEG moiety, resulting in rapid clearance of PEG-asparaginase, 81 but they can still respond to native E. coli asparaginase. As noted earlier, antibody testing is not readily available, and there are technical difficulties in measuring the serum asparagine level; thus, measuring the asparaginase level is considered a relatively reliable and feasible way to monitor treatment. In the absence of a monitoring tool, the serum albumin level may serve as a biomarker of asparaginase activity.
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Pancreatitis and thrombosis are two of the most serious and most frequent dose-limiting asparaginaserelated toxicities, occurring more often in patients 10 years of age or older than in younger patients. 82, 83 Concomitant administration of other drugs may potentiate or contribute to the risk and severity of 1 4 pancreatitis (e.g., glucocorticoid, mercaptopurine, trimethoprim sulfamethoxazole) and thrombosis (glucocorticoid). Although these complications rarely resulted in mortality, they pose significant morbidity and often recur with rechallenge. 82, 83 With low-molecular-weight heparin prophylaxis and close monitoring, most patients with thrombotic complications can complete the scheduled asparaginase treatment. 83 In one study, patients with mild pancreatitis were rechallenged after resolution of symptoms and normalization of pancreatic enzymes, with two thirds having a second episode of pancreatitis after receiving an average of 7 to 8 additional doses of asparaginase. 82 Whether the use of octreotide or short-acting Erwinia asparaginase can prevent or reduce the risk of recurrence of pancreatitis 84 require additional studies.
Pharmacogenomics-guided continuation (maintenance) treatment: gaining a therapeutic edge
The combination of weekly low-dose methotrexate and daily mercaptopurine, with or without pulses of dexamethasone and vincristine, constitutes the standard "backbone" of ALL continuation regimens.
Tailoring the dosages of methotrexate and mercaptopurine to the limits of tolerance has been associated with a better outcome. 74 In most clinical trials, both drugs are increased or decreased in parallel without ascertaining the genetic polymorphism status of thiopurine methyltransferase, even though the relationship between its genotype or phenotype and the clinical effects of mercaptopurine is well established. 85 The enzyme catalyzes S-methylation of thiopurines to inactive methylated metabolites.
Thus, patients with an inherited deficiency of this enzyme are at increased risk of mercaptopurineinduced toxicities because more parent drug is available for anabolism to active metabolites. We argue that the time has come to customize the dosage of mercaptopurine based on preemptive testing for thiopurine methyltransferase status. First, among patients with poor tolerance to continuation treatment, mercaptopurine dosage can be selectively reduced, while methotrexate can still be given at full dosage 1 5 in those with a deficiency of the enzyme. This approach has reduced the likelihood of acute myelosuppression without compromising disease control. [85] [86] [87] Second, patients with thiopurine methyltransferase deficiency are at greater risk for the development of mercaptopurine-induced myeloid malignancy, particularly if they receive high-dose mercaptopurine (e.g., 75 mg/m 2 per day). 88 Thioguanine is more potent than mercaptopurine, but its prolonged use at a dose above 40 mg/m 2 has been associated with profound thrombocytopenia, an increased risk of death, and an unacceptable rate of hepatic veno-occlusive disease (~20%). 89, 90 Hence, thioguanine is no longer used for continuation treatment; however, whether its short-term use can improve outcome, especially in terms of CNS control, without causing undue toxicity remains to be determined. Notably, thiopurine methyltransferase also has a significant impact on the pharmacokinetics of thioguanine, and patients with the enzyme deficiency are at an increased risk of developing hepatic veno-occlusive disease. 91 We recommend implementation of the guidelines for thiopurine therapy (updates at http://www.pharmgkb.org), based on the association between clinical effects and genotype/phenotype of the enzyme, as recently developed by the Clinical Pharmacogenetics Implementation Consortium. 85 In many clinical trials, weekly methotrexate is given orally for convenience and cost savings. We prefer to give it intravenously because this route offers a way to partly circumvent the problems of variable bioavailability and poor treatment adherence. Indeed, an adherence rate of less than 95% was associated with an increased risk of relapse in a recent COG study. 92 Although there are various methods to monitor treatment adherence to antimetabolite therapy such as measurement of erythrocyte mercaptopurine metabolite (thioguanine nucleotide) level or mean corpuscular volume, pill counts or electronic monitoring device, parenteral administration of methotrexate is a certain way to assure that the patient received at least one drug. We believe this approach was partly responsible for the improved prognosis of older adolescents treated in our Total XV study. 54 The dosages of methotrexate used in doses for the high-risk patients in the Dutch Childhood Oncology Group protocol ALL-9. 96 Despite these results, many leukemia therapists still prefer intrathecal methotrexate and are reluctant to omit cranial irradiation from protocols for high-risk patients.
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The mixed results of a randomized COG study (CCG 1952) for standard-risk ALL 20 has led to an ongoing debate over the characteristics of optimal intrathecal therapy. In that study, triple intrathecal therapy resulted in a significantly lower incidence of isolated CNS relapse than did treatment with intrathecal methotrexate (6-year cumulative risk: 3.4%±1.0% versus 5.9%±1.2%). The impact was even more pronounced in patients with a CNS2 status (6-year cumulative risk: 7.7%±5.3% vs.
23.0%±9.5%), a subset requiring intensified treatment to avert a high hazard of relapse. 97 However, significantly more hematological and testicular relapses occurred among patients treated with triple intrathecal therapy than among those receiving intrathecal methotrexate, resulting in a significantly inferior survival for the former group (90.3%±1.5% versus 94.4%±1.1%). 20 The COG investigators raised the possibility that intrathecal cytarabine or hydrocortisone somehow interferes with the egress of methotrexate from cerebrospinal fluid into blood, leading to less systemic exposure to methotrexate than does treatment with intrathecal methotrexate alone. 20 We favor another explanation: that so-called isolated CNS relapse could be an early manifestation of systemic relapse, and the improved CNS control secured with triple intrathecal treatment sets the stage for overt leukemic relapse in other sites subsequently. 97 Whatever the explanation, we would argue that triple intrathecal therapy used together with effective systemic chemotherapy, at least in patients at high risk of relapse, would allow cranial irradiation to be omitted in this subgroup. In this regard, a recent meta-analysis of randomized trials of CNS-directed therapy showed that adding intravenous methotrexate for patients treated with triple intrathecal therapy improves outcome by reducing both CNS and non-CNS relapses, whereas adding it for those treated with intrathecal methotrexate yields little benefit. 98 The case for eliminating prophylactic cranial irradiation can be summarized as follows. First, even among patients treated before 2000 with less effective chemotherapy regimens than those in contemporary use, the substitution of intravenous and intrathecal methotrexate therapy could yield
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From event-free survival comparable to that of cranial irradiation with additional intrathecal treatment. 98 Second, the remission retrieval rate is high for patients with isolated CNS relapse who did not receive prior prophylactic cranial irradiation. In this regard, all 11 patients with an isolated CNS relapse in our Total XV study 7 remain in subsequent remission after retrieval therapy for 4 to 11 years, and in all likelihood are cured of their leukemia. Third, patients who receive irradiation are at life-long risk of second cancers and other complications; 94, 95 indeed, any short-term gain in event-free survival with use of radiation may be abolished with prolonged follow-up. Fourth, there is no safe dose of cranial irradiation. In the ALL-BFM 90 study which employed 12 Gy cranial irradiation, the cumulative risk of second neoplasms had already reached 1.7% (95% confidence interval, 0.1% to 3.4%) at 15 years postinduction, 99 and is expected to increase with longer follow-up. In our current study, we further intensify triple intrathecal therapy during the early phase of remission induction in patients identified to have a higher risk of CNS relapse from Total XV study (i.e., T-cell immunophenotype, t(1;19)/TCF3-PBX1, and any CNS involvement by leukemic cells), 7 in an effort to prevent CNS relapse entirely.
Even though encouraging neuropsychological results, with the exception of adverse effects on complex fine-motor functioning, were reported for patients treated on the Dutch Childhood Oncology Group protocol ALL-9 with chemotherapy only, 100 we realize that intensive systemic chemotherapy as well as a high cumulative dose of intrathecal therapy can impair neurocognitive and neuromuscular function. [101] [102] [103] [104] Thus, future studies should focus on determining the optimal doses of chemotherapy needed to avoid over-or under-treatment.
Future directions
Treatments developed and refined over the past several decades have resulted in high cure rates and a large population of leukemia survivors. Studying the long-term health complications of these adult survivors will help to develop less toxic treatments while preserving earlier gains in efficacy. The individualized based on the estimates of clearance to achieve a desired systemic exposure to the drug.
As shown, in a patient estimated to have low clearance (40 ml/min/m 2 ) (A), the dosage should be lowered to achieve the desired steady-state plasma concentration to reduce potential toxicities (B).
Those patients with high clearance have dosages increased. 
